Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-019184
Filing Date
2024-05-14
Accepted
2024-05-14 14:43:05
Documents
62
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 830772
2 ex31-1.htm EX-31.1 17447
3 ex31-2.htm EX-31.2 17181
4 ex32.htm EX-32 7974
  Complete submission text file 0001493152-24-019184.txt   4051046

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE pvct-20240331.xsd EX-101.SCH 34740
6 XBRL CALCULATION FILE pvct-20240331_cal.xml EX-101.CAL 44317
7 XBRL DEFINITION FILE pvct-20240331_def.xml EX-101.DEF 130220
8 XBRL LABEL FILE pvct-20240331_lab.xml EX-101.LAB 268263
9 XBRL PRESENTATION FILE pvct-20240331_pre.xml EX-101.PRE 211867
65 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 528541
Mailing Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929
Business Address 800 S. GAY STREET SUITE 1610 KNOXVILLE TN 37929 (866) 594-5999
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36457 | Film No.: 24943543
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)